Personalised Nutrition for Healthy Living (PROTEIN)

Personalised Nutrition for Healthy Living: PROTEIN

The topic of diet and physical activity are of great importance in the treatment of T2D. In the daily routine of a practice or clinic, a doctor has an average of eight minutes per patient, leaving little time for lifestyle issues (Irving et al. 2017). An individualised procedure requires more time and therefore more resources. Currently, an app can be programmed with evidence-based information so that it provides appropriate personalised behavioural recommendations via machine learning. The user gets direct feedback and can make a behavioural change himself. On the one hand, this approach allows better use of doctor-patient time and, on the other hand, the patient learns through positive reinforcement in such a way that his or her behaviour change is supported and reinforced in the longer term and potentially sustainably.

The aim of this intervention pilot study within the scope of the EU-Horizon 2020 project is to investigate lifestyle support through a mobile app and wearables to improve lifestyle (personalised nutrition) and important metabolic outcomes in patients with type 2 diabetes or prediabetes. In addition, exploratory genetic and microbiome data will be explored to answer the question of personalisation of the recommendations.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus, Type 2; PreDiabetes
• Intervention / Treatment: Other: Usage of the PROTEIN-Application

Detailed Description

An inadequate diet and increasing sedentary lifestyle are major contributors to the rise of non-communicable diseases. Individualized recommendations can lead to a healthier lifestyle. The scientific evidence of the effectiveness of health apps offering personalized recommendations is limited.

The aim of this intervention pilot study within the scope of the EU-Horizon 2020 project is to investigate lifestyle support through a mobile app and wearables to improve lifestyle (personalised nutrition) and important metabolic outcomes in patients with type 2 diabetes or prediabetes. The Investigators want to asess whether the use of this mobile application that incorporates information of wearables (continuous glucose monitoring and fitness tracker), improves lifestyle and metabolic outcomes in patients with type 2 diabetes (T2D) or prediabetes. Our primary outcome is to improve time in range (TIR) by 5%.

It is a prospective randomized control pilot trial with an intervention period of 12 weeks. Participants will use the Protein app, a continuous glucose monitoring system (CGM) and an activity tracker to collect real world data to enable personalisation.

In order to identify the effect of the PROTEIN-Application, 300 participants with T2DM or prediabetes will be randomly allocated into two groups: the (1) start-group or the (2) wait-group. The start-group will use an activity tracker, a CGM and the PROTEIN app for 12 weeks followed by a six-week period without the app, but they will use the wearables. The wait-group will use an activity tracker and a CGM, but not the PROTEIN app for six weeks followed by a period of 12 weeks using the PROTEIN app. This study design allowed us to have a control group within the whole cohort and clearly see the influence of the PROTEIN app.

• Study Type: Interventional
• Enrollment (Actual): 27
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • State of Berlin
    • Berlin, State of Berlin, Germany, 12203
      • Charité Univesitätsmedizin Berlin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• ≥ 18 years of age
• Diabetes Type 2 or Prediabetes
• BMI: 20-kg kg/m2
• Android Smart Phone/ Tablet use
• In good physical health
• Able to provide written informed consent

Exclusion Criteria:

• Severe endocrine, gastrointestinal, metabolic, cardiovascular, pulmonary, inflammatory or psychiatric disorder
• Active or recent relevant cancer
• Currently receiving treatment with Insulin
• People with disordered eating (such as anorexia nervosa etc.)
• Those who are not be able to provide written consent

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Start-Group; The Start-Group starts with the Protein-Application and wereables for 3 Months and afterwards uses only wereables for 6 Weeks.	Other: Usage of the PROTEIN-Application; Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.
Experimental: Wait-Group; The Wait-Group starts with 6 Weeks of using only wereables and afterwards adds the usage of the Protein-Application.	Other: Usage of the PROTEIN-Application; Participants were randomly distributed into 2 groups: (1) Start-Group used the developed Application and wereables to investigate the effect of this support. Participants used the devices and the App for 3 Months followed by a 6-Weeks time of only using wereables and no app, to be able to compare the effects of the Application. (2) The Wait-Group used wereables for 6 Weeks before adding the Protein-App for also 3 Months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Improvement of Time In Range (TIR) by 5%	Our primary objective is to increase the time in range (TIR) of the study participants by 5%	12 Weeks
Improve eating behavior towards healthier choices	Improve eating behaviour towards healthier choices during the intervention time	12 Weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adherence to dietary recommendations of the app	Adherence to dietary recommendations of the PROTEIN-App	12 Weeks
Improvement of glycaemic metabolism	Fasting glucose, HbA1c, HOMA-IR	12 Weeks
Reduction in sedentary time	Reduction in sedentary time, defined as: Activity time through fitness trackers or increase in physical activity or increase in steps per day	12 Weeks
Aproximation of the energy intake	Approximation of the energy intake (calorie intake and distribution of macronutrients) towards the agreed goals	12 Weeks
Measurable change in the faecal microbiome	Measurable change in the faecal microbiome by extraction of DNA and its analysis to identify the relevant species of bacteria	12 Weeks
Calculation of the Polygenic Risk Score	Calculation of the Polygenic Risk Score by Isolation of DNA from whole blood	12 Weeks

Collaborators and Investigators

• Sponsor: Prof. Dr. med. Andreas F. H. Pfeiffer
• Collaborators: European Union
• Investigators: Study Director: Lazaros Gymnopoulos, Dr, Information Technologies Institute, Centre for Research and Technology Hellas

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2020
• Primary Completion (Actual): November 30, 2022
• Study Completion (Actual): November 30, 2022

Study Registration Dates

• First Submitted: May 4, 2023
• First Submitted That Met QC Criteria: July 11, 2023
• First Posted (Actual): July 18, 2023

Study Record Updates

• Last Update Posted (Actual): May 7, 2026
• Last Update Submitted That Met QC Criteria: May 3, 2026
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Metabolic Diseases; Glucose Metabolism Disorders; Diabetes Mellitus; Nutritional and Metabolic Diseases; Diabetes Mellitus, Type 2; Prediabetic State
• Other Study ID Numbers: PROTEIN

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No